Preparation and Characterization of Solid Lipid Nanoparticle (SLN) of Gliclazide

  • ANISA AMALIA UNIVERSITAS INDONESIA
  • MAHDI JUFRI UNIVERSITAS INDONESIA
  • EFFIONORA ANWAR UNIVERSITAS INDONESIA

Abstract

 Solid lipid nanoparticle (SLN) has been proposed as colloidal carriers using solid lipid as matrix material. In this study, gliclazide-loaded solid lipid nanoparticle has been prepared with high shear homogenization and freeze drying method using stearic acid as lipid material, Tween 80 and PEG 400 as surfactant, ethanol as`co-solvent and lactose as cryoprotectant. Characterization was performed on SLN dosage from before and after freeze drying, which includes the analysis of particle size, zeta potential value, morphology analysis and entrapment efficiency of gliclazide. Results indicated gliclazide
can be formulated in SLN dosage form using high shear homogenization and freeze drying method. The morphology study revealed that the prepared SLN were irregular in shape with mean particle size of 878.0 ± 246.3 nm and 745.8 ± 204.0 nm. Zeta potensial values of gliclazide-loaded SLN  were found –

References

1. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009. 71(4):349-58.
2. Sinha VR, Srivastava S, Goel H, Vinay J. Solid lipid nanoparticles (SLN’s) – Trends and implications in drug targeting. International Journal of Advances in Pharmaceutical Sciences. 2010. 1:212-38.
3. Ingle US, Bankar VH, Gaikwad PD, Sunil PP. Solubility enhancement of oral hypoglycemic agent by solid dispersion technique. International Journal of Applied Biology and Pharmaceutical Technology IIJABPT. 2011. 2(2):301-6.
4. Krishnaiah, Yellela SR. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. JBB. 2010. 2( 2):028-36.
5. Bandarkar, Farzana S, Ibrahim SK. Lyophilled gliclazide-poloxamer solid dispersions for enhancement of in vitro and in vivo bioavaibility. Int J Pharm Pharm Sci. 2011. 3(2): 122-7.
6. Biswal S, Sahoo J, Murthy PN, Giradkar RP, Avari JG. Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000. AAPS Pharm Sci Tech. 2008. 9(2): 563-70.
7. Sarkar A, Tiwari A, Bhasin PS, Mobby M. Pharmacological and pharmaceutical profile of gliclazide: A review. Journal of Applied Pharmaceutical Science. 2011. 01(09):11-9.
8. Das S, Anumita C. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm Sci Tech. 2011. 12(1): 62-76.
9. Kamboj S, Bala S, Anroop BN. Solid lipid nanoparticles: An effective lipid based technology for poorly water soluble drugs. International Journal of Pharmaceutical Sciences Review and Research. 2010. 5(2):78-90.
10. De Souza ALR, Andreani T, Nunes FM, Cassimiro DL, De Almeida AE, Ribeiro CA, Sarmento VHV, Gremião MPD, Silva AM, Eliana BS. Loading of praziquantel in the crystal lattice of solid lipid nanoparticles. J. Therm Anal Calorim. 2011. DOI 10.1007/s10973-011-1871-4.
11. Triplett II MD, James FR. Optimization of β-carotene loaded solid lipid nanoparticles preparation using high shear homogenization technique. J Nanopart Res. 2009. 11:601–14.
12. Abdelbary G, Rania HF. Diazepam-loaded solid lipid nanoparticles: design and characterization. AAPS Pharm Scitech. 2009. 10(1): 211-9.
13. Bourezg Z, Bourgeois S, Pressenda S, Shehada T, Hatem F. Redispersible lipid nanoparticles of spironolactone obtained by three drying methods. Colloids and Surfaces A: Physicochem Eng Aspects. 2012.
14. El-Kamel AH, Al-Fagih IM, Ibrahim AA. Testosterone solid lipid nanoparticles for transdermal drug delivery. Formulation and physicochemical characterization. Journal of Microencapsulation. 2007. 24(5): 457-75.
15. Nimbalkar UA, Dhoka MV, Sonawane PA. Solid lipid nanoparticles for enhancement of oral bioavilability of cefpodoxime proxetil. IJPS. 2011. 2(11):2974-82.
16. Prajapati SK, Tripathi P, Ubaidulla U, Vikas AD. Design and development of gliclazide mucoadhesive microcapsules: in vitro and in vivo evaluation. AAPS PharmSciTech. 2008. 9(1):224-30.
17. Demіrtürk E, Levent Ö. Solubility and dissolution properties of gliclazide. FABAD J. Pharm. Sci. 2004. 29: 21-5.
18. Mäder K, Wolfgang M. Lipospheres in drug targets and delivery. Chapter 1 : Solid lipid nanoparticles – Concepts, procedures, and physicochemical aspects. CRC Press LL. 2005. 1-25.
19. Zhang L, Lei L, Yu Q, Yun C. The effects of cryoprotectants on the freeze-drying of ibuprofen- loaded solid lipid microparticles (SLM). European Journal of Pharmaceutics and Biopharmaceutics. 2008. 69:750–9.
How to Cite
AMALIA, ANISA; JUFRI, MAHDI; ANWAR, EFFIONORA. Preparation and Characterization of Solid Lipid Nanoparticle (SLN) of Gliclazide. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 13, n. 1, p. 108-114, apr. 2015. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/134>. Date accessed: 22 nov. 2024.
Citation Formats
Issue
Vol 13 No 1 (2015): JIFI
Section
Articles
License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.